Dana-Farber Research Publication 02.01.2023
-
by n/a
February 1, 2023
-
25 min
5 Key Takeaways
-
1
High-dose melphalan increases mutational burden in multiple myeloma at relapse.
-
2
Osimertinib and savolitinib show promise against acquired resistance in lung cancer.
-
3
Genetic testing can identify 13% of cancer diagnoses linked to pathogenic variants.
-
4
Racial disparities noted in opioid access for older cancer patients.
-
5
Research continues to explore effective cancer education strategies.
Dana-Farber Cancer Institute's Research News highlights significant advances in cancer treatment, including a study demonstrating that high-dose melphalan treatment increases mutational burden in multiple myeloma patients. A combination therapy of osimertinib and savolitinib has shown promise in addressing acquired resistance in non-small cell lung cancer. Other notable studies discuss the barriers to genetic education in cancer risk assessment and disparities in opioid access among older cancer patients. These findings are critical for enhancing cancer care and treatment strategies.
Listen Tab content
